John F Tarlton, D L Easty
In Europe and North America, retinoblastoma has a reported incidence ranging from 1 in 14 000 to 1 in 36 000 live births '-5 and is the most common ocular malignancy affecting children and infants. Early diagnosis allows the application of a number of therapies directed at localised disease, including external beam and plaque radiotherapy, cryotherapy, and photocoagulation, although the principal treatment accounting for the high cure rate of around 90% is enucleation, which is still carried out in over half of all cases. The justification for such radical therapy is the poor prognosis once the tumour escapes the eye, and the high mortality from metastases.6
In the developing countries ofAfrica and Asia the picture is different. The higher reported incidence in many areas,7-" coupled with a lower incidence ofocular malignant melanoma in particular racial groups results in retinoblastoma being the commonest ocular tumour in all age groups. Moreover, late diagnosis and treatment lead to a correspondingly high rate of mortality due to metastatic spread, approaching 100% in some areas.'0 Therefore the inability to deal effectively with metastatic retinoblastoma results in a high mortality in areas where medical care is limited and the extensive use of prophylactic enucleation in developed countries. Despite the efficacy of current therapeutic intervention, there remains a need for further investigation into improvements in treatment of metastatic disease.
Recent advances in the understanding ofthe cancer process are due largely to the advent of molecular genetics and the use of monoclonal antibodies, and perhaps the greatest contribution of such techniques has been in studies of retinoblastoma. The occasional association of the familial predisposition to retinoblastoma with a visible chromosome deletion at 13ql4,'2-'4 and the linkage to the gene coding for esterase-D,'3 11 6 confirmed the genetic basis for this disease. Epidemiological evidence led Knudson to formulate the 'two hit' hypothesis for the tumorigenesis of retinoblastoma, postulating that both copies of the viable gene must be inactivated by two independent mutational events (or 'hits').' 8 An individual with the familial predisposition has inherited one inactive gene, such that only one subsequent mutational event is necessary, during the susceptible stage of embryonic development, to cause a retinoblast to become malignant.
Retinoblastoma was the first cancer to be identifie7d with a tumour suppressor gene, or anti-oncogene,'" to have this gene, RB1, located and cloned, and its protein product, pl1 0' ', isolated.419 The inheritance is autosomally dominant in individuals with a single germline mutation due to the high probability of a second ' Immunohistochemistry in defining cellular origin The immunochemical reactivity of tumour samples and cell lines such as Y7927 and WERI RB128 has been investigated using monoclonal antibodies which recognise markers associated with particular tissues and cell types. Such markers include retinal S antigen,2"3' inter-retinoid binding protein,3' opsin,3' 32 and rhodopsin,33 all associated with photoreceptors; S100 and glial fibrillary acidic protein3""33"37 associated with glial cells; neuron specific enola'se,'3234 38 tetanus toxin and dopamine B hydroxylase,37 neurofilaments and synaptophysin,"39 all characteristic of neuronal cells. From the presence of these markers, a tumour origin from photoreceptors, glial, or neuronal cells has been postulated, as well as from a primitive common progenitor cell.
An alternative approach has been to equate antigenic heterogeneity with cell types, and therefore the differentiation potential oftheir common progenitor, the cell oforigin of the tumour. By correlating with the known cell lineage of developing embryonic retinal cells, this allows definition of the tumour stem cell in terms of normal retinal progenitors (Figs 1, 2, and 3) . Results from this work,' and the weight of Figure 1 Immunohistochemical reactivity profiles ofretinoblastoma, adult, andfetal retina with respect to seven differentially marking monoclonal antibodies. Tumour may be distinguished from nornal retinal cell types using a panel ofantibodies. NF= dissemination. The use of monoclonal antibodies in identifying retinoblastoma cells, particularly at distal sites, is proving to be important in prognostic evaluation.
Ocular toxocariasis results from infestation of the eye with the larval stage of the dog ascarid Toxocara canis. Immunoassays using the serum of affected individuals are diagnostic for this disease in most cases,'42 although this cannot be used to positively exclude retinoblastoma.
The reliability of diagnostic aqueous humour cytological assays following anterior chamber paracentesis, may be enhanced by the use of monoclonal antibodies. This may be important in confirmation of Coats' disease42 and in distinguishing between diffuse infiltrating retinoblastoma, requiring immediate enucleation, and inflammatory hypopyon associated with uveitis, where non-invasive examination by ultrasound or computed tomography may prove inconclusive.'4 46 Similarly, the cytological analysis of fine needle biopsies may be improved by the use of immunocytochemical techniques, although possible tumour seeding in this procedure may limit its use. l 4
The two main risk factors influencing prognosis that may be identified in enucleated eyes are optic nerve involvement, particularly at the resection margin, and trans-scleral extension.4849 Other factors which are generally indicative of terminal disease are central nervous system (CNS) involvement and bone marrow metastasis.5' Generally such features can be identified by conventional histological procedures, although their reliability and accuracy may be enhanced by immunohistochemical staining.
Immunohistological techniques may be used to detect small numbers of invasive retinoblastoma cells within the sclera, because they uniformly express determinants not associated with choroidal-scleral tissue or inflammatory cells. An example of this is neural cell adhesion molecule (NCAM), for which there are a number of specific monoclonal antibodies, including UJ13A4'5' and ERIC-1.525 Differentiation of optic nerve infiltration by retinoblastoma cells is more problematic, as many of the determinants which may potentially distinguish the tumour cells from surrounding neuronal tissue, such as anti-Thy 1 45 or anti-opsin,3 32 are those which are not uniformly or consistently expressed by the tumour cells. This may be circumvented by applying staining to a sufficient number of invasive cells such that the subpopulation expressing the antigen in question is represented in the sample, or by using a panel of monoclonal antibodies on separate histological sections.4855' We have demonstrated that, by using such a panel of antibodies, it is possible to distinguish the tumour cells from individual cell types of adult and fetal retina by their immunoreactivities alone (Fig  1) . These procedures require substantial tumour infiltration in order to provide sufficient tissue for analysis, in which case conventional techniques would probably prove adequate.
These and many other problems associated with the use of monoclonal antibodies would be resolved were a retinoblastoma specific antigen to be identified. Such a marker is proving elusive, not only in retinoblastoma but in other cancers, despite much investigation and many failed candidates. Researchers in our laboratories are presently engaged in a study isolating cell surface glycoproteins by lectin affinity, and separation by sodium dodecyl sulphate polyacrylamide gel electrophoresis in an effort to identify membrane components unique to retinoblastoma.
Cerebrospinal fluid (CSF) cytology, without the assistance of immunochemistry, has been used in assessing CNS involvement, 57 Primary ocular retinoblastoma is usually diagnosed as a result of clinical examination alone and the extent of the tumour is evaluated in a similar way. Differential diagnosis from simulating lesions often requires the use of ancillary tests, and orbital or optic nerve extension cannot be assessed readily by superficial examination. Typical characteristics of advanced ocular retinoblastoma are tumour necrosis and calcification, which may be identified by computed tomography scanning and ultrasonography," 4 and local extensions may be visualised further by magnetic resonance imaging.67 The success of such techniques in diagnosing and evaluating primary retinoblastoma has limited the application of immunoscintigraphy in imaging localised disease. There is potential for this technique, though, in evaluating metastatic progression where alternative scanning procedures may prove inadequate. Presently the technique is not considered reliable for secondary lesions of less than 1 cm3, and therefore micrometastases, which contribute greatly to the progression of this disease, may escape detection. On the other hand, non-specific localisations, which are a major limitation in therapeutic targeting, may in many cases be predicted and discounted.
It is possible that improvements in tumour localisation, with production of monoclonal antibodies of greater specificity, along with advances in imaging techniques, may lead to the application of immunoscintigraphy in the evaluation of metastatic retinoblastoma, although it is unlikely that this technique will ever have the sensitivity needed for identifying microscopic lesions.' Therapeutic uses of monoclonal antibodies A major factor inhibiting the use of new treatments in retinoblastoma, such as immunotherapy and antibody targeting, is the perceived high success rate with current treatments.
The survival rate of around 90% of cases in developed countries is achieved at the cost of the loss of one or both eyes in over 50% of cases4' and impairment in visual acuity in still more. Although maintenance of sight is an important consideration, survival is the first priority and therapy which does not guarantee comparable life expectancy with established treatment is justifiably viewed with some caution, presenting an ethical dilemma in the relative priorities of mortality and morbidity.6 This is particularly the case with speculative or experimental therapy, such as immunotargeting, when these have not been validated for cancers in which conventional treatment is less successful. In addition to enucleation, successful therapy relies heavily on techniques such as external beam and episcleral plaque irradiation, cryotherapy, and photocoagulation, which are generally limited in their applications to localised disease. 4 42 Disseminated retinoblastoma responds poorly to systemic therapy, and this greatly contributes to the high mortality associated with this disease once it is allowed to spread. 6 The use of chemotherapy has not delivered significant improvements in patient survival, and has now been abandoned in some centres.669 Cyclophosphamide is the most popular drug for single agent therapy, but increasingly multiagent regimens are being applied, such as cyclophosphamide, vincristine, and Adriamycin (doxorubicin).'°Intrathecal methotrexate has also been applied when CNS involvement is indicated.643 The aim of chemotherapy is selective elimination of tumour cells while limiting damage to normal tissues, requiring an adequate differential response between tumour and normal tissue. This has not been achieved in the case of metastatic retinoblastoma, for which prohibitively toxic doses are required to eliminate the tumour cells. 43 It has long been recognised that antibodies may provide this missing selectivity70 and their use in therapeutic cancer targeting remains a principal goal for oncologists. The promise of specific antibody directed cancer therapy has proved elusive,"72 although the obstacles which must be overcome are now more clearly defined. These include a lack of tumour specific target antigens,7""5 low antigen densities,74 heterogeneity and antigenic modulation in tumours (leading to treatment resistant clones),7"7 low absolute immunoconjugate localisations,7879 rapid clearance of conjugates from circulation and tissues,75 poor penetration of high molecular weight reagents,75 non-specific retentions and interactions of targeting and effector components, and the patient's own immune reaction to foreign immunoglobulin (human antimouse antibody or HAMA response).728'8' Furthermore, the number of effector units which may be linked to each carrier antibody limits the therapeutic targeting and raises the toxicity required from each conjugate.82
Targeting of chemotherapeutic drugs currently in use, such as methotrexate, has shown enhanced specificity for cancer cells.82 Nevertheless, the low doses reaching the tumour demand a greater toxicity than is provided by such reagents. Highly potent plant toxins, such as ricin and abrin, have been used successfully in monoclonal antibody directed killing of tumour cells in experimental models of malignancies,8"85 including retinoblastoma,76 but non-specific toxicity has precluded their use in systemic human therapy. The targeting of plant toxins, though, has found a practical use in the purging of metastatic cancer cells from bone marrow samples before autologous transplant. 85 Purging of bone marrow samples may also be carried out by mechanical separation, using magnetic microsphere conjugates. This technique has been successfully applied in Applications ofmonoclonal antibodies in the investigation, diagnosis, and ts .,^retinoblasto patients with haematogenous metastasis of retinoblastoma, using a cocktail of six monoclonal antibodies raised against neuroblastoma. 50 Therapeutic use of antibody guided radionuclides is a natural extension of radioimmunoscintigraphy, and application of radiolabelled monoclonal antibodies has produced efficacious results in xenograft animal models of human malignancy." 87 In order to deliver toxic levels of reagents to tumours, a high dose must be applied, which in turn results in unacceptable accumulations in the blood and non-target tissues. These residues remain toxic until clearance of reagents is complete, during which time they are dose limiting. For this reason a number of research groups are looking at ways of achieving preclearance of unbound antibody before the application of the toxic component.
Antibody-directed enzyme prodrug therapy (ADEPT) delivers, via the monoclonal antibody component, an enzyme that remains non-toxic during conjugate clearance, and is potentiated only when a prodrug is administered; this is converted by the enzyme to an active drug at the tumour site (Fig 4) . As clearance of the unbound delivery component is completed before the prodrug is applied, much higher concentrations of immunoconjugates may be given, with corresponding improvements in absolute levels of tumour localisation. Also, a potentially large number of prodrug molecules may be activated by a single enzyme, thus overcoming the numerical restriction which applies when the effector is directly conjugated to the delivery component. 73759192 Although the large molecular mass of enzyme conjugates may present problems of penetration for these reagents, the relatively small drug and toxin molecules generated by these enzymes will be able to diffuse far better than the targeted components themselves. This allows improved access by the effector component, and removes the necessity for each target cell to be individually localised.
An alternative approach aimed at pretargeting the tumour before potentiation by the effector component, makes use of the powerful and specific interaction between avidin and biotin (dissociation constant 10-'). The tumour localising monoclonal antibody is labelled with either avidin or biotin, and when clearance has established the optimum tumour/ blood and tumour/tissue ratios, the effector component is applied, linked to biotin or avidin respectively, and targeting is mediated by the affinity of two labelling molecules. The clearance rate of the biotin or avidin linked effector component is still significant, but is thought to be considerably faster than for the equivalent immunoconjugate, and may be accelerated by application of 'cold' avidin or biotin. 93 The production of hybrid bispecific antibodies by fusing two hybridoma cell lines,8' or by combining monomeric Fab fragments, allows crosslinking of tumour cell surface antigens, bound by one Fab region, with a drug or toxin recognised by the other binding site695 (Fig 5) . As previously, clearance of the targeting antibody may be achieved before the application of the effector component. Bispecific monoclonal antibodies may also be used to induce the patient's own immune response, by crosslinking tumour cells with activated T cells. 9 A different two stage strategy is to pretarget the tumour with the non-radioactive boron-10 isotope, which remains harmless until irradiated with neutrons, when it disintegrates into high energy cc particles. Enhancement of selectivity is achieved if irradiation can be confined to the tumour site."
These pretargeting techniques provide the potential of increased levels of tumour targeting, but the problems of antigen specificity, density, and modulation remain. Investigations being undertaken in our laboratories into binary enzyme targeting (BET) are attempting to address these problems. BET would be accomplished by delivering two different enzymes to malignant cells using monoclonal antibodies which recognise different tumour associated antigens. Both enzymes need to be present simultaneously in order to drive a two'stage reaction activating a prodrug, or pretoxin, which is applied when the tumour/tissue ratio is optimal. In this way enhanced selectivity of targeting may be achieved by combining the specificities of both delivery monoclonal antibodies (Fig 6) . As there are less stringent demands on individual antigen specificities, those expressed consistently, and at a higher density, may be selected as targets. 52 The Figure 7 Chimaeric and 'hunanised' monoclonal antibodies.'2 Is strategies for minimising the impact of the human anti-mouse antibody reaction are to reduce or eliminate the murine component of the antibodies. This may be achieved by using human monoclonals, produced by hybridoma technology, or by transforming human peripheral B lymphocytes with Epstein-Barr virus. Practical and ethical problems preclude routine immunisations of human subjects, although in vitro alternatives are now available, and collection of sufficient numbers of specific B cells, as well as the lack of satisfactory fusion partners, restricts their application. An approach which is under extensive investigation, is to combine the low immunogenicity of human antibodies with the antigen specificity of mouse antibodies. This may be achieved either by producing chimeric antibodies, in which only the variable (V) domains are of murine origin, or by engineering 'humanised' antibodies by recombinant DNA technology, which are entirely human except for the complementarity determining regions (CDRs) of the antigen binding site, which are defined by the gene sequences provided by the immunised mouse"81 (Fig 7) .
The problem of poor tumour localisation is aggravated by the limited penetration across blood-tissue barriers and into solid tumour masses. This problem may be addressed by the use of the antibody fragments; monomeric Fab or dimeric F(ab')2. Not only are these fragments able to penetrate better in circumstances where molecular mass restricts tumour access, but they are also cleared more rapidly from the circulation, enhancing tumour/blood ratios, and do not interact with Fc receptors.79 A recent development is the production of recombinant engineered Fv antibody fragments, which are the smallest units retaining antigen-specific binding capability.79
Another possible approach is to improve penetration of reagents into tumours by modulating tissue barriers themselves. Increased blood flow can be induced in tumours by low doses of external radiation, by injection of complement fixing anti-tumour monoclonal antibodies, or by systemic or targeted application of cytokines.9 Accessibility to the intercellular space is influenced by a number of factors, including tight junctions formed by cell-cell interactions, and the presence of, and cellular adhesion to, basement membrane components. Cellular interactions are controlled chiefly by the expression of adhesion molecules, such as neural cell adhesion molecules (NCAMs) in retinoblastoma, and basement membranes interact via cell surface integrins. Access to intercellular spaces may be improved by blocking the activity of such molecules, utilising inhibitors or specific markers of adhesion molecules, such as the anti-NCAM monoclonal antibodies UJ13A, 5.1Hll, A2B5,4°and ERIC-1.5253 Blocking of cellular adhesion may significantly increase metastatic potential of a tumour, therefore further investigation is needed before selecting appropriate reagents for therapeutic use. An alternative to the use of monoclonal antibodies in specific delivery of therapeutic reagents, is to utilise conjugates of growth factors, hormone analogues, or integrin recognition motifs to target functional cell surface receptors. Many cancers originate through aberrant overexpression of growth factor receptors of the protein kinase family, due to proto-oncogene amplification, or the loss of control functions. Such possible oncogene associated targets include receptors for epidermal growth factor (oncogenes erb B, c-neu), colony stimulating factor (oncogene c-fms), stem cell factor (oncogene c-kit), and insulin (oncogene v-ros). group.bmj.com on June 22, 2017 -Published by http://bjo.bmj.com/ Downloaded from cells is dependent to a large extent upon particular cell-cell and cell-matrix interactions, and therefore cell adhesion molecules and integrins may present suitable targets for localisation using their native ligands or specific recognition motifs. It is unlikely that such targets would alone provide adequate specificity, but may be utilised in combination for BET, or used in compartmentalised administrations. Summary Monoclonal antibodies have had mixed fortunes since coming to the attention of the research and medical communities; disappointment at their failure to live up to early expectations has often obscured their real value. Understanding, and in some cases overcoming, their limitations has prompted a revival in interest based on their realistic potential.
Regulation of malignant characteristics, such as proliferation and dissemination, is a highly complex process involving interchange between growth factors and membrane bound receptors, cellular and matrix interactions, and enzyme mediated remodelling of the interstitial environment in favour ofgrowth and invasion. There is likely to be increasing interest in immunohistochemical and western blot analyses of specific markers of malignancy, leading to greater understanding of tumour progression and metastasis, and antibody interactions may even provide means of modulating these processes. For example, we are currently engaged in a western blot evaluation of NCAM expression in retinoblastoma, and results indicate a link between tumour expression of low binding affinity embryonic type NCAMs and metastatic potential (unpublished data).
Progress in the therapeutic uses of monoclonal antibodies in retinoblastoma depend to a large extent on advances made in treating other malignancies, as it is only when clear benefits are demonstrable, in terms of patient survival and morbidity, that current low risk strategies will be abandoned. It is likely, therefore, that some of the prospective therapies, aimed at overcoming the limitations of inadequate specificity, inappropriate toxicity, and poor reagent localisation shall in time be applied to retinoblastoma.
Although the potential for tumour spread leads to prophylactic use of enucleation in developed countries, metastatic retinoblastoma is still regarded as a Third World problem. For this reason potential therapy aimed at controlling disseminated disease should be both inexpensive and readily portable for access to outlying regions. Providing cold storage facilities are available, monoclonal antibody conjugates are eminently portable; nevertheless, they are also extremely expensive to produce, limiting their use in circumstances in which there are great demands on meagre health care budgets. It is very important, therefore, to look into cheap and efficient new methods of production, such as prokaryote expression systems, in order to broaden their application in both the laboratory and the clinic. Furthermore, reagents and methodologies should be standardised so as to minimise requirement for expensive specialised equipment or training of personnel. 
